Form 4: Bausch + Lomb Director Receives Equity Grant

Director Russel C. Robertson acquired 15,842 common shares of Bausch + Lomb Corporation via an annual RSU grant.

Summary

• Director Russel C. Robertson was granted 15,842 restricted share units (RSUs) on May 26, 2026.
• The grant was issued under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
• The transaction price for the equity award was $15.78 per share.
• Following this transaction, the director's total beneficial ownership increased to 94,260 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard annual incentive grant indicates stable corporate governance practices.

Negatives

• None identified.

Risks

• Market price volatility of BLCO shares could impact the ultimate value of the RSU grant.

Future Outlook

The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders.

Industry Context

StockSavvy.ai notes that annual equity grants to non-employee directors are a standard practice in the pharmaceutical and medical device industry to ensure long-term alignment with shareholder interests.

Comparison to Industry Standards

• The use of an Omnibus Incentive Plan for director compensation is consistent with standard corporate governance practices for large-cap healthcare companies.
• The vesting schedule tied to the annual meeting is a common industry benchmark for board compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; represents standard director compensation.

Next Steps

• Vesting of the RSUs prior to the next annual meeting of shareholders.

Key Dates

Keywords

Bausch + Lomb, BLCO, Director Compensation, Insider Transaction, Equity Grant, Form 4